FDA Cracks Down Again on Kratom Products

By | June 30, 2019

National Institute on Drug Abuse: “What is Kratom?”

News release, FDA.

Michael E. Schatman, PhD, director of research and network development, Boston Pain Care; assistant professor of public health and community medicine, Tufts University School of Medicine.

Robert Glatter, MD, emergency medicine doctor, Lenox Hill Hospital, New York.

Eric Webb, spokesperson, Cali Botanicals, Rancho Cordova, CA.

Morbidity and Mortality Weekly Report, April 12, 2019.

National Institute on Drug Abuse.

Drug Enforcement Administration.

News release, University of Florida.

International Journal of Drug Policy: “Kratom policy: The challenge of balancing therapeutic potential with public safety.”

Speciosa.org: “Petition Please do not make Kratom a Schedule I Substance,” “Kratom Legality Map.”

WebMD Health

Read More:  The access specialist presents high-performance products and new services